Evaxion reports three‑year durable responses in melanoma vaccine trial
Evaxion A/S presented three‑year follow‑up data from its phase‑2 trial of the personalized cancer vaccine EVX‑01 in advanced melanoma. All patients remaining in the study showed no tumor progression and maintained the clinical responses observed at two years. The results confirm a 75% objective response rate with 25% complete responses and a 92% clinical benefit rate at the two‑year mark. The company will share the data at the ESMO 2026 Congress and in a webinar.
Why it matters
The company says the durable data strengthen EVX‑01’s clinical package and could facilitate partnership discussions. Investors may view the data as a positive catalyst for the stock and future financing opportunities.
Key facts
- 1All patients at three‑year follow‑up maintained clinical responses with no tumor progression observed. stocktitan.net
- 2The two‑year data showed a 75% objective response rate, including 25% complete responses. stocktitan.net
- 3At two years, 92% of responding patients continued to show clinical benefit with no relapses. rttnews.com
- 454% of patients experienced a deepened response after EVX‑01 treatment. investing.com
- 586% of vaccine neoantigens generated specific T‑cell responses at two‑year follow‑up. investing.com
- 6EVAX closed at $2.83 on October 16, 2026, up 0.71% (pre‑market $2.91, up 2.83%). rttnews.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.